Healthcare provider profile · identity verified

Abdulrahman Rahim

Family Practice · PORTLAND, OR · NPI 1558723825

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	205	69
Amlodipine Besylate	Amlodipine Besylate	172	56
Lisinopril	Lisinopril	148	49
Gabapentin	Gabapentin	139	39
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	122	15
Levothyroxine Sodium	Levothyroxine Sodium	122	37
Losartan Potassium	Losartan Potassium	119	39
Rosuvastatin Calcium	Rosuvastatin Calcium	95	38
Metformin Hcl	Metformin Hcl	89	27
Albuterol Sulfate Hfa	Albuterol Sulfate	82	39
Oxycodone Hcl	Oxycodone Hcl	82	15
Metoprolol Succinate	Metoprolol Succinate	77	27
Omeprazole	Omeprazole	76	33
Eliquis	Apixaban	72	18
Tamsulosin Hcl	Tamsulosin Hcl	58	20
Hydrochlorothiazide	Hydrochlorothiazide	54	17
Olmesartan Medoxomil	Olmesartan Medoxomil	53	15
Chlorthalidone	Chlorthalidone	52	17
Simvastatin	Simvastatin	49	suppressed
Furosemide	Furosemide	47	19
Ozempic	Semaglutide	47	suppressed
Trazodone Hcl	Trazodone Hcl	45	14
Carvedilol	Carvedilol	43	15
Famotidine	Famotidine	43	14
Duloxetine Hcl	Duloxetine Hcl	42	12
Metformin Hcl Er	Metformin Hcl	42	19
Escitalopram Oxalate	Escitalopram Oxalate	37	16
Jardiance	Empagliflozin	37	11
Potassium Chloride	Potassium Chloride	32	suppressed
Januvia	Sitagliptin Phosphate	31	suppressed
Sertraline Hcl	Sertraline Hcl	31	11
Atenolol	Atenolol	30	13
Finasteride	Finasteride	29	suppressed
Baclofen	Baclofen	28	suppressed
Fluticasone Propionate	Fluticasone Propionate	28	suppressed
Meloxicam	Meloxicam	27	15
Metoprolol Tartrate	Metoprolol Tartrate	26	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	26	13
Citalopram Hbr	Citalopram Hydrobromide	25	suppressed
Pravastatin Sodium	Pravastatin Sodium	25	suppressed
Spironolactone	Spironolactone	25	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	25	suppressed
Allopurinol	Allopurinol	24	11
Bupropion Xl	Bupropion Hcl	24	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	24	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	23	19
Cinacalcet Hcl	Cinacalcet Hcl	23	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	23	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	23	suppressed
Torsemide	Torsemide	23	suppressed
Alendronate Sodium	Alendronate Sodium	22	suppressed
Cephalexin	Cephalexin	22	17
Ezetimibe	Ezetimibe	21	suppressed
Pregabalin	Pregabalin	21	suppressed
Azelastine Hcl	Azelastine Hcl	20	17
Valsartan	Valsartan	20	suppressed
Morphine Sulfate Er	Morphine Sulfate	19	suppressed
Tizanidine Hcl	Tizanidine Hcl	19	suppressed
Fluconazole	Fluconazole	18	13
Glimepiride	Glimepiride	18	suppressed
Mirtazapine	Mirtazapine	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	14
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	17	12
Montelukast Sodium	Montelukast Sodium	17	suppressed
Clopidogrel	Clopidogrel Bisulfate	16	suppressed
Ketoconazole	Ketoconazole	16	11
Naproxen	Naproxen	16	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	16	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	15	suppressed
Nystatin	Nystatin	15	12
Prednisone	Prednisone	15	14
Testosterone	Testosterone	15	suppressed
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Lovastatin	Lovastatin	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Symbicort	Budesonide/Formoterol Fumarate	14	suppressed
Clonazepam	Clonazepam	13	suppressed
Farxiga	Dapagliflozin Propanediol	13	suppressed
Lidocaine	Lidocaine	13	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error